Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aptiv PLC (APTV) vs ARK Genomic Revolution ETF (ARKG) Price & Performance

Aptiv PLCTrade
ARK Genomic Revolution ETFTrade

Price performance (Past 24H)

Key statistics

Aptiv PLC vs ARK Genomic Revolution ETF — how do they compare? Aptiv PLC trades at $59.43 (market cap $12.82B), while ARK Genomic Revolution ETF trades at $41.21. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.

APTVARKG
Market Cap
$12.82B
Sector
Consumer CyclicalSector/Thematic
52-Week High
$76.82$43.57
52-Week Low
$52.57$23.09
Enterprise Value
$19.53B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aptiv PLC

APTV trades at $60.57, up 1.19% with a bearish technical signal but strong analyst support. Recent earnings beats and a consensus price target of $78.57 suggest upside potential. Revenue grew to $20.40B in 2025, though net margins compressed to 1.77%. The company announced Q2 2026 results on August 4, 2026, with expectations of $1.42 EPS.

Outlook is mixed: bullish fundamentals from earnings momentum and low P/S of 0.64 contrast with technical weakness and margin pressures. Risks include debt levels and competitive threats, but institutional buy ratings (63.6%) highlight confidence in long-term growth from automotive technology demand.

ARK Genomic Revolution ETF

ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.

The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.

Returns comparison

Trailing returns across standard periods

About Aptiv PLC

Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.

Read more on APTV

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG